We are live on ! Find out more
UBS Group

UBS Group Portfolio holdings

AUM $666B
1-Year Est. Return 30.12%
 

UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.

This Fund
S&P 500
This Quarter Est. Return
+8.15%
1 Year Est. Return
+30.12%
3 Year Est. Return
+86.21%
5 Year Est. Return
+101.56%
10 Year Est. Return
+367.78%
AUM
$287B
AUM Growth
+$27.6B
Cap. Flow
+$6.59B
Cap. Flow %
2.29%
Top 10 Hldgs %
12.98%
Holding
8,864
New
808
Increased
4,306
Reduced
2,684
Closed
688

Sector Composition

Rank Sector Weight
1 Technology 9.82%
2 Financials 7.38%
3 Healthcare 6.65%
4 Consumer Discretionary 5.46%
5 Industrials 5.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TNAV
5501
DELISTED
Telenav Inc.
TNAV
$232K ﹤0.01%
47,584
+6,630
+16% +$32.3K
MFT
5502
DELISTED
BLACKROCK MUNIYIELD INVESTMENT QUALITY FUND
MFT
$232K ﹤0.01%
17,157
-7,029
-29% -$94.5K
ADMA icon
5503
ADMA Biologics
ADMA
$2.24B
$231K ﹤0.01%
57,675
-6,549
-10% -$28.5K
SFIX
5504
CALL
Stitch Fix
SFIX
$538M
$231K ﹤0.01%
9,000
-76,000
-89% -$1.77M
UBX
5505
DELISTED
Unity Biotechnology
UBX
$231K ﹤0.01%
3,206
+969
+43% +$68.4K
SRE.PRB
5506
DELISTED
Sempra 6.75% Mandatory Convertible Preferred Stock, Series B
SRE.PRB
$231K ﹤0.01%
1,938
+1,863
+2,484% +$219K
FVL
5507
DELISTED
First TrustValue Line 100 Exchange-Traded
FVL
$231K ﹤0.01%
10,116
-900
-8% -$20.1K
JHY
5508
DELISTED
Nuveen High Income 2020 Target Term Fund Common Shares of Beneficial Interest
JHY
$231K ﹤0.01%
23,582
+2,865
+14% +$28.4K
COKE icon
5509
Coca-Cola Consolidated
COKE
$12.6B
$230K ﹤0.01%
8,080
-12,620
-61% -$353K
CRMD icon
5510
CorMedix
CRMD
$577M
$230K ﹤0.01%
31,649
+13,417
+74% +$82K
GCO icon
5511
PUT
Genesco
GCO
$426M
$230K ﹤0.01%
+4,800
New +$199K
GTX icon
5512
Garrett Motion
GTX
$5.52B
$230K ﹤0.01%
23,006
-140
-0.6% -$1.43K
GRX
5513
Gabelli Healthcare & Wellness Trust
GRX
$146M
$229K ﹤0.01%
19,875
+5,829
+41% +$62.9K
KVHI icon
5514
KVH Industries
KVHI
$157M
$229K ﹤0.01%
20,601
+7,364
+56% +$78.2K
WMGI
5515
PUT
DELISTED
Wright Medical Group Inc
WMGI
$229K ﹤0.01%
7,500
AXTI icon
5516
AXT Inc
AXTI
$5.56B
$228K ﹤0.01%
52,370
+22,211
+74% +$71.3K
GLU
5517
Gabelli Utility & Income Trust
GLU
$115M
$228K ﹤0.01%
12,065
-980
-8% -$18.3K
MR
5518
DELISTED
Montage Resources Corporation Common Stock
MR
$228K ﹤0.01%
28,713
+8,495
+42% +$44.3K
ESGL
5519
DELISTED
Invesco ESG Revenue ETF
ESGL
$228K ﹤0.01%
6,575
+751
+13% +$25.1K
VRTSP
5520
DELISTED
Virtus Investment Partners, Inc. 7.25% Series D Mandatory Convertible Preferred Stock
VRTSP
$228K ﹤0.01%
2,246
+1,316
+142% +$126K
SNDX icon
5521
Syndax Pharmaceuticals
SNDX
$1.8B
$227K ﹤0.01%
25,795
+3,990
+18% +$29.3K
AD
5522
Array Digital Infrastructure
AD
$3.03B
$227K ﹤0.01%
6,260
-2,128
-25% -$74.6K
ZYNE
5523
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$227K ﹤0.01%
37,595
+2,642
+8% +$18.1K
TCFC
5524
DELISTED
The Community Financial Corporation Common Stock
TCFC
$227K ﹤0.01%
6,371
+1,753
+38% +$59.4K
NBEV
5525
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
$227K ﹤0.01%
124,971
+62,217
+99% +$147K

Similar funds

UBS Group's Q4 2019 Portfolio in Review

As of Q4 2019, UBS Group held 8,864 positions worth $287B, up 11% from $260B the previous quarter. Its ten largest holdings account for 13% of the portfolio.

UBS Group's Q4 2019 filing shows 808 new, 4,306 increased, 2,684 reduced and 688 closed positions. Its largest new stake was Bristol-Myers Squibb Company Contingent Value Rights: 5,302,748 shares worth $16M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $1.3B.

By sector, the portfolio is most concentrated in Technology at 9.8% of assets, up from 9.5% a quarter earlier, followed by Financials and Healthcare.

  • UBS Group's largest Q4 2019 buy was Bristol-Myers Squibb Company Contingent Value Rights: 5,302,748 shares worth $16M.
  • UBS Group added most to UBS Group in Q4 2019, an estimated $1.48B increase.
  • UBS Group's biggest Q4 2019 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.3B.
  • UBS Group fully exited Altaba Inc in Q4 2019, selling an estimated $759M.
  • UBS Group's ten largest holdings make up 13% of its $287B portfolio in Q4 2019.
  • UBS Group opened 808 new positions and closed 688 in Q4 2019.
  • UBS Group's portfolio value rose 11% quarter-over-quarter to $287B.

Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.